Loading...
XNASUG
Market cap46mUSD
Jan 08, Last price  
10.06USD
1D
-0.45%
1Q
-16.86%
Jan 2017
-35.10%
Name

United-Guardian Inc

Chart & Performance

D1W1MN
XNAS:UG chart
P/E
17.90
P/S
4.25
EPS
0.56
Div Yield, %
0.99%
Shrs. gr., 5y
0.06%
Rev. gr., 5y
-4.59%
Revenues
11m
-14.28%
11,123,47512,134,99612,195,67211,888,56212,292,14713,276,98413,723,07414,338,51213,825,76415,416,89313,449,67914,006,24410,776,86712,968,20513,769,40113,599,08410,986,08113,929,62912,698,50310,885,154
Net income
3m
+0.46%
2,475,0582,617,4832,737,2323,544,3083,162,9313,878,9633,799,6924,716,5304,830,7805,903,3094,050,4164,606,9292,581,1423,844,2904,352,3314,761,7113,304,9784,658,5422,569,5122,581,370
CFO
3m
+24.53%
2,172,5763,172,0302,076,7974,157,0583,412,3854,337,4484,093,3184,437,1295,380,7475,805,0864,480,7525,199,9722,290,4443,992,2874,950,4124,476,1113,594,2405,313,2772,525,1693,144,480
Dividend
Jul 23, 20240.35 USD/sh
Earnings
Mar 20, 2025

Profile

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally. The company offers cosmetic ingredients, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL NATURAL consisting of natural ingredients for cosmetic use; LUBRAJEL MARINE; LUBRASIL II SB, a special formulation of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base; LUBRAJEL II XD; B-122, a powdered lubricant that is used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; KLENSOFT, a surfactant, which is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL LC and LUBRAJEL FA that are LUBRAJEL formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial product to treat infections in the urinary bladder, and localized infections in the peritoneum, as well as eye, ear, nose and throat, and sinuses. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and development primarily related to the development of cosmetic ingredients. It markets its products through marketing partners, distributors, and wholesalers. The company was founded in 1942 and is based in Hauppauge, New York.
IPO date
Mar 17, 1980
Employees
23
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
10,885
-14.28%
12,699
-8.84%
Cost of revenue
5,944
6,487
Unusual Expense (Income)
NOPBT
4,942
6,211
NOPBT Margin
45.40%
48.91%
Operating Taxes
669
658
Tax Rate
13.55%
10.60%
NOPAT
4,272
5,553
Net income
2,581
0.46%
2,570
-44.84%
Dividends
(459)
(3,123)
Dividend yield
1.39%
6.51%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
(436)
(361)
Net debt
(9,094)
(6,484)
Cash flow
Cash from operating activities
3,144
2,525
CAPEX
(166)
(75)
Cash from investing activities
4,728
898
Cash from financing activities
(459)
(3,123)
FCF
4,340
4,804
Balance
Cash
9,094
6,484
Long term investments
Excess cash
8,550
5,849
Stockholders' equity
11,389
9,267
Invested Capital
2,403
2,841
ROIC
162.94%
217.63%
ROCE
43.39%
68.40%
EV
Common stock shares outstanding
4,594
4,594
Price
7.20
-31.03%
10.44
-36.53%
Market cap
33,079
-31.03%
47,965
-36.53%
EV
23,985
41,481
EBITDA
5,047
6,347
EV/EBITDA
4.75
6.54
Interest
1,619
Interest/NOPBT
26.07%